|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang GL and Lin ZB: The immunomodulatory
effect of lentinan. Yao Xue Xue Bao. 31:86–90. 1996.(In Chinese).
PubMed/NCBI
|
|
3
|
Lei LS and Lin ZB: Effect of Ganoderma
polysaccharides on T cell subpopulations and production of
interleukin 2 in mixed lymphocyte response. Yao Xue Xue Bao.
27:331–335. 1992.PubMed/NCBI
|
|
4
|
Zhang Q and Lin Z: Study on antitumor
activity and mechanism of Ganoderma polysaccharides B. Zhongguo
Zhong Xi Yi Jie He Za Zhi. 19:544–547. 1999.(In Chinese).
PubMed/NCBI
|
|
5
|
Jiang W, Zhao S, Xu L, Lu Y, Lu Z, Chen C,
Ni J, Wan R and Yang L: The inhibitory effects of xanthohumol, a
prenylated chalcone derived from hops, on cell growth and
tumorigenesis in human pancreatic cancer. Biomed Pharmacother.
73:40–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Venè R, Benelli R, Minghelli S, Astigiano
S, Tosetti F and Ferrari N: Xanthohumol impairs human prostate
cancer cell growth and invasion and diminishes the incidence and
progression of advanced tumors in TRAMP mice. Mol Med.
18:1292–1302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshimaru T, Komatsu M, Tashiro E, Imoto
M, Osada H, Miyoshi Y, Honda J, Sasa M and Katagiri T: Xanthohumol
suppresses oestrogen-signalling in breast cancer through the
inhibition of BIG3-PHB2 interactions. Sci Rep. 4:73552014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kunnimalaiyaan S, Sokolowski KM,
Balamurugan M, Gamblin TC and Kunnimalaiyaan M: Xanthohumol
inhibits Notch signaling and induces apoptosis in hepatocellular
carcinoma. PLoS One. 10:e01274642015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kunnimalaiyaan S, Trevino J, Tsai S,
Gamblin TC and Kunnimalaiyaan M: Xanthohumol-mediated suppression
of Notch1 signaling is associated with antitumor activity in human
pancreatic cancer cells. Mol Cancer Ther. 14:1395–1403. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benelli R, Venè R, Ciarlo M, Carlone S,
Barbieri O and Ferrari N: The AKT/NF-κB inhibitor xanthohumol is a
potent anti-lymphocytic leukemia drug overcoming chemoresistance
and cell infiltration. Biochem Pharmacol. 83:1634–1642. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fowler DH: Rapamycin-resistant effector
T-cell therapy. Immunol Rev. 257:210–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu W, Celeridad M, Sankar S, Webb DR and
Bennett BL: CC-4047 promotes Th1 cell differentiation and
reprograms polarized human Th2 cells by enhancing transcription
factor T-bet. Clin Immunol. 128:392–399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szabo SJ, Kim ST, Costa GL, Zhang X,
Fathman CG and Glimcher LH: A novel transcription factor, T-bet,
directs Th1 lineage commitment. Cell. 100:655–669. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu J, Yamane H, Cote-Sierra J, Guo L and
Paul WE: GATA-3 promotes Th2 responses through three different
mechanisms: Induction of Th2 cytokine production, selective growth
of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res.
16:3–10. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ouyang W, Löhning M, Gao Z, Assenmacher M,
Ranganath S, Radbruch A and Murphy KM: Stat6-independent GATA-3
autoactivation directs IL-4-independent Th2 development and
commitment. Immunity. 12:27–37. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kurata H, Lee HJ, O'Garra A and Arai N:
Ectopic expression of activated Stat6 induces the expression of
Th2-specific cytokines and transcription factors in developing Th1
cells. Immunity. 11:677–688. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh S and Hwang ES: The role of protein
modifications of T-bet in cytokine production and differentiation
of T helper cells. J Immunol Res. 2014:5896722014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kidd P: Th1/Th2 balance: The hypothesis,
its limitations, and implications for health and disease. Altern
Med Rev. 8:223–246. 2003.PubMed/NCBI
|
|
19
|
Liao D, Luo Y, Markowitz D, Xiang R and
Reisfeld RA: Cancer associated fibroblasts promote tumor growth and
metastasis by modulating the tumor immune microenvironment in a 4T1
murine breast cancer model. PLoS One. 4:e79652009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hong M, Jiang Z and Zhou YF: Effects of
thermotherapy on Th1/Th2 cells in esophageal cancer patients
treated with radiotherapy. Asian Pac J Cancer Prev. 15:2359–2362.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshino S, Yoshimura K, Suzuki N, Iida M,
Yoshida S, Maeda Y, Maeda K, Hazama S and Oka M: Immunoregulatory
effects of PSK on the Th1/Th2 balance and regulatory T-cells in
patients with colorectal cancer. Gan To Kagaku Ryoho. 37:2234–2236.
2010.(In Japanese). PubMed/NCBI
|
|
22
|
Romagnani S, Maggi E and Del Prete G: An
alternative view of the Th1/Th2 switch hypothesis in HIV infection.
AIDS Res Hum Retroviruses. 10:iii–ix. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Crane IJ and Forrester JV: Th1 and Th2
lymphocytes in autoimmune disease. Crit Rev Immunol. 25:75–102.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsuzaki J, Tsuji T, Imazeki I, Ikeda H
and Nishimura T: Immunosteroid as a regulator for Th1/Th2 balance:
Its possible role in autoimmune diseases. Autoimmunity. 38:369–375.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun CZ Zhihong, Feng Liu, et al:
Inhibition of breast cancer cell survival by Xanthohumol via
modulating Notch signaling pathway in vivo and in vitro. Oncology
Letters. 15585229–12;2015.
|
|
26
|
Kast RE: Ribavirin in cancer
immunotherapies: Controlling nitric oxide augments cytotoxic
lymphocyte function. Neoplasia. 5:3–8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matar P, Rozados VR, Gervasoni SI and
Scharovsky GO: Th2/Th1 switch induced by a single low dose of
cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol
Immunother. 50:588–596. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Naito S, von Eschenbach AC, Giavazzi R and
Fidler IJ: Growth and metastasis of tumor cells isolated from a
human renal cell carcinoma implanted into different organs of nude
mice. Cancer Res. 46:4109–4115. 1986.PubMed/NCBI
|
|
29
|
Guo HW, Yun CX, Hou GH, Du J, Huang X, Lu
Y, Keller ET, Zhang J and Deng JG: Mangiferin attenuates TH1/TH2
cytokine imbalance in an ovalbumin-induced asthmatic mouse model.
PLoS One. 9:e1003942014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ubukata H, Motohashi G and Tabuchi T,
Nagata H, Konishi S and Tabuchi T: Evaluations of
interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as
prognostic indicators in gastric cancer patients. J Surg Oncol.
102:742–747. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao J, Zhang Q, Xu J, Guo L and Li X:
Clinical significance of serum miR-21 in breast cancer compared
with CA153 and CEA. Chin J Cancer Res. 25:743–748. 2013.PubMed/NCBI
|
|
32
|
Tan QX, Qin QH, Yang WP, Mo QG and Wei CY:
Prognostic value of Ki67 expression in HR-negative breast cancer
before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol.
7:6862–6870. 2014.PubMed/NCBI
|
|
33
|
Shurin MR, Lu L, Kalinski P, Stewart-Akers
AM and Lotze MT: Th1/Th2 balance in cancer, transplantation and
pregnancy. Springer Semin Immunopathol. 21:339–359. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feili-Hariri M, Falkner DH and Morel PA:
Polarization of naive T cells into Th1 or Th2 by distinct
cytokine-driven murine dendritic cell populations: Implications for
immunotherapy. J Leukoc Biol. 78:656–664. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma J, Liu H and Wang X: Effect of ginseng
polysaccharides and dendritic cells on the balance of Th1/Th2 T
helper cells in patients with non-small cell lung cancer. J Tradit
Chin Med. 34:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saxena R and Kaur J: Th1/Th2 cytokines and
their genotypes as predictors of hepatitis B virus related
hepatocellular carcinoma. World J Hepatol. 7:1572–1580. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hong CC, Yao S, McCann SE, Dolnick RY,
Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, et al:
Pretreatment levels of circulating Th1 and Th2 cytokines, and their
ratios, are associated with ER-negative and triple negative breast
cancers. Breast Cancer Res Treat. 139:477–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kiyofuji A, Yui K, Takahashi K and Osada
K: Effects of xanthohumol-rich hop extract on the differentiation
of preadipocytes. J Oleo Sci. 63:593–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Casaschi A, Maiyoh GK, Rubio BK, Li RW,
Adeli K and Theriault AG: The chalcone xanthohumol inhibits
triglyceride and apolipoprotein B secretion in HepG2 cells. J Nutr.
134:1340–1346. 2004.PubMed/NCBI
|
|
40
|
Costa R, Rodrigues I, Guardão L, Lima JQ,
Sousa E, Soares R and Negrão R: Modulation of VEGF signaling in a
mouse model of diabetes by xanthohumol and 8-prenylnaringenin:
Unveiling the angiogenic paradox and metabolism interplay. Mol Nutr
Food Res. 61:doi: 10.1002/mnfr.2016004882017. View Article : Google Scholar
|
|
41
|
Sasazawa Y, Kanagaki S, Tashiro E, Nogawa
T, Muroi M, Kondoh Y, Osada H and Imoto M: Xanthohumol impairs
autophagosome maturation through direct inhibition of
valosin-containing protein. ACS Chem Biol. 7:892–900. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee IS, Lim J, Gal J, Kang JC, Kim HJ,
Kang BY and Choi HJ: Anti-inflammatory activity of xanthohumol
involves heme oxygenase-1 induction via NRF2-ARE signaling in
microglial BV2 cells. Neurochem Int. 58:153–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dorn C, Bataille F, Gaebele E, Heilmann J
and Hellerbrand C: Xanthohumol feeding does not impair organ
function and homoeostasis in mice. Food Chem Toxicol. 48:1890–1897.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Choi JM, Kim HJ, Lee KY, Choi HJ, Lee IS
and Kang BY: Increased IL-2 production in T cells by xanthohumol
through enhanced NF-AT and AP-1 activity. Int Immunopharmacol.
9:103–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cho YC, You SK, Kim HJ, Cho CW, Lee IS and
Kang BY: Xanthohumol inhibits IL-12 production and reduces chronic
allergic contact dermatitis. Int Immunopharmacol. 10:556–561. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong
M, Chen X, Xiang R and Tan X: Alginic acid-coated chitosan
nanoparticles loaded with legumain DNA vaccine: Effect against
breast cancer in mice. PLoS One. 8:e601902013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mosmann TR and Sad S: The expanding
universe of T-cell subsets: Th1, Th2 and more. Immunol Today.
17:138–146. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sparano A, Lathers DM, Achille N,
Petruzzelli GJ and Young MR: Modulation of Th1 and Th2 cytokine
profiles and their association with advanced head and neck squamous
cell carcinoma. Otolaryngol Head Neck Surg. 131:573–576. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pernis AB and Rothman PB: JAK-STAT
signaling in asthma. J Clin Invest. 109:1279–1283. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mowen KA and Glimcher LH: Signaling
pathways in Th2 development. Immunol Rev. 202:203–222. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chang HC, Han L, Goswami R, Nguyen ET,
Pelloso D, Robertson MJ and Kaplan MH: Impaired development of
human Th1 cells in patients with deficient expression of STAT4.
Blood. 113:5887–5890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen J, Wang Y, Mei Z, Zhang S, Yang J, Li
X, Yao Y and Xie C: Radiation-induced lung fibrosis in a
tumor-bearing mouse model is associated with enhanced type-2
immunity. J Radiat Res. 57:133–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
